Key result
Pre-operative use of beta-blockers reduced the risk of admission for heart failure by 13% within 2 years after CABG surgery, with greater benefit in patients with ejection fraction <35%.
Why the study?
Does pre-operative use of beta-blockers reduce heart failure admissions in patients undergoing CABG surgery?
Cohort (n=65,377)
Yes
Does pre-operative use of beta-blockers reduce heart failure admissions in patients undergoing CABG surgery?
Answers are grounded in this paper and cite their sources.
Pre-operative beta-blocker use is associated with a 13% reduced risk of heart failure admission within 2 years after CABG surgery, particularly in patients with low ejection fraction.
AIMS: Factors related to hospitalization for heart failure (HF) following coronary artery bypass grafting (CABG) surgery were studied. METHODS AND RESULTS: Patients (n = 65 377) undergoing CABG surgery in New Jersey from 1998 to 2007 were identified from the state cardiac surgery database; subsequent hospitalizations for HF were assessed using the Myocardial Infarction Data Acquisition System database. Patients were classified based on pre-operative ejection fraction (EF). Multivariate models were used to identify factors related to HF admission and mortality. Post-CABG HF admission rates among patients with pre-operative EF <35% increased over the 10-year period (P = 0.02), but no significant trend was seen among patients with EF ≥35%. Independent factors associated with post-CABG HF admission within 2 years were: EF, age, female gender, Black race, smoking, diabetes, renal disease, hypertension, and cerebrovascular disease. Pre-operative use of beta-blockers increased over the years (P < 0.0001) and reduced the risk of admission for HF by 13%, with greater benefit in patients with lower EF. Mortality remained unchanged from 1998 to 2007, averaging 1.8% in-hospital and 5.1% and 7.2% at 1-year and 2-year follow-up, respectively. CONCLUSIONS: Pre-operative EF is a strong predictor of HF admission within 2 years after CABG surgery. The use of beta-blockers decreased HF admission after CABG, especially in patients with EF <35%. Despite the more pronounced benefit and increasing use of beta-blockers in patients with a low EF, HF admission rates in this group of patients are rising. This suggests that more comprehensive management of factors associated with HF is necessary.
No takes yet. Share an insight, caveat, or question.
Moreyra et al. (2012) conducted a cohort in Coronary artery bypass grafting (CABG) surgery (n=65,377). Pre-operative use of beta-blockers vs. No pre-operative use of beta-blockers was evaluated on Admission for heart failure within 2 years (13% risk reduction). Pre-operative use of beta-blockers reduced the risk of admission for heart failure by 13% within 2 years after CABG surgery, with greater benefit in patients with ejection fraction <35%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: